|
|
Article: Supplemental NDA submitted for Aldara cream, 5%.
- Article from:
- Drug Week
- Article date:
- July 11, 2003
CopyrightCOPYRIGHT 2003 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2003 JUL 11 - (NewsRx.com & NewsRx.net) -- 3M announced that the company has submitted a supplemental new drug application (sNDA) with the U.S. Food and Drug Administration (FDA) to market Aldara (imiquimod) Cream, 5%, an immune response modifier (IRM), for the treatment of superficial basal cell carcinoma (sBCC), a common form of non-melanoma skin cancer.
Approximately 1.3 million new cases of non-melanoma skin cancer occur in the United States each year. Of these, almost 1 million are basal cell carcinomas (BCCs). Aldara cream, currently the leading prescription treatment for external genital and perianal warts, is the first IRM application submitted for the ...